OGM Is Taking Over

Europe, the US, and Asia Are Ditching Microarrays Faster Than Anyone Expected (Based on global conference participation, number of studies, and user‑community data) 

Europe is currently the strongest region for OGM adoption, driven by the European Society of Human Genetics (ESHG).  Europe hosts the largest number of independent OGM validation studies across constitutional genetics, hematologic malignancies, and solid tumors. 

Bionano Genomics: The Apple of AMP’s Eye

Bionano Genomics’ OGM has become the unexpected darling of the Association for Molecular Pathology. AMP is famously tough, its community is built on data, not buzzwords, yet year after year, OGM keeps stealing the spotlight. Independent labs from around the world are showing up with case studies, validation cohorts, and head‑to‑head comparisons that make traditional cytogenetic tools look like relics from another era. 

OGM keeps delivering the kind of structural‑variant clarity, resolution, and clinical impact that molecular pathologists have been begging for. In a landscape crowded with incremental upgrades, OGM feels like the first genuinely new cytogenomic capability in decades, and AMP’s growing fascination with it says more about the technology’s momentum than any marketing campaign ever could.